Outlook Therapeutics, Inc. — Director's Dealing 2021

Oct 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-10-05

Reporting Person: Haddadin Yezan Munther (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-05	Stock Option (Right to Buy)	$2.12	A	47335	Acquired	2031-10-05	Common Stock (47335)	Direct

Footnotes

F1: The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.